Published in Alzheimers Dement (Amst) on December 18, 2016
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA (1997) 10.75
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Silent brain infarcts: a systematic review. Lancet Neurol (2007) 5.76
Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology (1993) 5.72
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology (1995) 3.95
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology (2008) 3.76
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 3.67
Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol (2002) 3.48
Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci (2002) 3.11
The pathobiology of vascular dementia. Neuron (2013) 3.07
Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke (2004) 2.92
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol (2008) 2.71
Staging and natural history of cerebrovascular pathology in dementia. Neurology (2012) 2.61
Microinfarct pathology, dementia, and cognitive systems. Stroke (2011) 2.61
Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology (2003) 2.60
Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol (2013) 2.55
The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis (2009) 2.54
Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology (2009) 2.47
Diffusion-weighted magnetic resonance imaging in acute stroke. Stroke (1998) 2.40
Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab (2008) 2.38
Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis (2009) 2.34
Transcranial amelioration of inflammation and cell death after brain injury. Nature (2013) 2.34
AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol (2005) 2.31
Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol (2002) 2.27
Healthy diet and lifestyle and risk of stroke in a prospective cohort of women. Neurology (2014) 2.21
Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol (1997) 2.18
Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol (1990) 2.18
Blood-brain barrier breakdown in the aging human hippocampus. Neuron (2015) 2.17
Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology (2006) 2.06
Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke (2010) 2.04
Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol (2008) 2.03
Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology (2008) 2.00
Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry (2008) 1.99
Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke (2004) 1.96
Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol (2008) 1.91
Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol (2011) 1.91
Estimating cerebral microinfarct burden from autopsy samples. Neurology (2013) 1.87
The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke (1995) 1.87
White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol (1993) 1.86
Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol (2008) 1.74
The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol (2015) 1.73
Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke (2011) 1.70
White matter hyperintensities and their penumbra lie along a continuum of injury in the aging brain. Stroke (2014) 1.68
Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology (2012) 1.66
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Superficial siderosis in the general population. Neurology (2009) 1.52
Reduction of CSF and blood flow artifacts on FLAIR images of the brain with k-space reordered by inversion time at each slice position (KRISP). AJNR Am J Neuroradiol (2001) 1.52
In vivo detection of cerebral cortical microinfarcts with high-resolution 7T MRI. J Cereb Blood Flow Metab (2012) 1.49
Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab (2012) 1.47
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol (2013) 1.43
Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol (2010) 1.36
Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord (2009) 1.34
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement (2014) 1.33
Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther (2012) 1.30
Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology (2013) 1.29
Coevolution of white matter hyperintensities and cognition in the elderly. Neurology (2012) 1.28
Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol (2014) 1.27
Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci (2013) 1.27
FLAIR and diffusion MRI signals are independent predictors of white matter hyperintensities. AJNR Am J Neuroradiol (2012) 1.27
Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord (2006) 1.26
Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke (2005) 1.26
Treatment of acute ischemic stroke. N Engl J Med (2000) 1.24
Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology (2010) 1.22
Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol (2008) 1.22
Sex differences in stroke. J Cereb Blood Flow Metab (2012) 1.21
Magnetic resonance signal abnormalities in asymptomatic individuals: their incidence and functional correlates. Eur Neurol (1989) 1.18
Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport (2009) 1.11
Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology (2014) 1.10
Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci (2000) 1.08
Cerebral perfusion is associated with white matter hyperintensities in older adults with heart failure. Congest Heart Fail (2013) 1.07
Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke (2015) 1.07
Neuropathology of Alzheimer's disease and other dementias. Clin Geriatr Med (2001) 1.06
White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging (2014) 1.06
Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology (2015) 1.05
White matter abnormalities and cognition in a community sample. Arch Clin Neuropsychol (2009) 1.04
Presence and progression of white matter hyperintensities and cognition: a meta-analysis. Neurology (2014) 1.00
A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol (2012) 0.98
Diffusion-weighted MRI for evaluation of acute stroke. Neurology (1998) 0.97
Silent infarcts and cerebral microbleeds modify the associations of white matter lesions with gait and postural stability: population-based study. Stroke (2012) 0.97
The pathology of ischemic-vascular dementia: an update. J Neurol Sci (2002) 0.97
Silent cerebral microbleeds on susceptibility-weighted imaging of patients with ischemic stroke and leukoaraiosis. Neurol Res (2008) 0.94
Antemortem MRI findings associated with microinfarcts at autopsy. Neurology (2014) 0.93
Blood pressure reduction for vascular risk: is there a price to be paid? Stroke (2005) 0.93
Cerebral microbleeds: old leaks and new haemorrhages. Int J Stroke (2006) 0.93
Vascular parkinsonism: a clinical review. Eur Neurol (2008) 0.93
Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment. Hum Brain Mapp (2013) 0.92
Stroke genetics: a review and update. J Stroke (2014) 0.91
Focal hemosiderin deposits and β-amyloid load in the ADNI cohort. Alzheimers Dement (2013) 0.91
Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology (2010) 0.91
Understanding the pathology of vascular cognitive impairment. J Neurol Sci (2004) 0.90
Microbleeds are independently related to gait disturbances in elderly individuals with cerebral small vessel disease. Stroke (2010) 0.90
Microinfarct disruption of white matter structure: a longitudinal diffusion tensor analysis. Neurology (2014) 0.89
Sex differences in the causes and consequences of white matter hyperintensities. Neurobiol Aging (2007) 0.88
A three-dimensional study of brain string vessels using celloidin sections stained with anti-collagen antibodies. J Neurol Sci (2002) 0.87
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol (2014) 1.89
Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol (2014) 1.56
An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun (2016) 1.45
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement (2015) 1.17
Estimating long-term multivariate progression from short-term data. Alzheimers Dement (2014) 0.99
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol (2016) 0.95
Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging (2014) 0.94
Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging (2014) 0.89
Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement (2016) 0.89
Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiol Aging (2014) 0.87
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiol Aging (2014) 0.86
Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiol Aging (2014) 0.85
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement (2015) 0.83
Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord (2014) 0.82
Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement (2016) 0.82
Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging (2013) 0.81
Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. Neuroimage (2015) 0.81
Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiol Aging (2015) 0.80
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimers Dement (2014) 0.80
Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement (2015) 0.80
Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimers Dement (2016) 0.80
Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther (2016) 0.79
Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging (2014) 0.79
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging (2014) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. J Alzheimers Dis (2016) 0.78
Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimers Dement (2013) 0.78
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement (2016) 0.78
Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Med (2016) 0.77
Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism Relat Disord (2015) 0.77
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition. J Alzheimers Dis (2016) 0.77
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. J Alzheimers Dis (2016) 0.77
Alzheimer's disease: The next frontier-Special Report 2017. Alzheimers Dement (2017) 0.76
Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol (2017) 0.76
RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiol Aging (2016) 0.76
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging (2015) 0.76
Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. J Alzheimers Dis (2015) 0.76
Massachusetts Alzheimer's Disease Research Center: Progress and challenges. Alzheimers Dement (2015) 0.76
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging (2017) 0.75
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord (2016) 0.75
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst) (2016) 0.75
Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. Neuroimage Clin (2016) 0.75
Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiol Aging (2016) 0.75
Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex (2016) 0.75
Life-course blood pressure in relation to brain volumes. Alzheimers Dement (2016) 0.75
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimers Dement (2016) 0.75
A robust biomarker of large-scale network failure in Alzheimer's disease. Alzheimers Dement (Amst) (2017) 0.75
An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Dement (2016) 0.75
Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30-91 Years and the Importance of Adjusting for Sex. J Int Neuropsychol Soc (2020) 0.75
Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain (2017) 0.75
Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol (2017) 0.75
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain (2017) 0.75
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement (2016) 0.75
Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. J Alzheimers Dis (2016) 0.75
Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. Alzheimers Dement (2017) 0.75
Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimers Dement (N Y) (2017) 0.75
Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. J Neurooncol (2017) 0.75
Neurocognition in individuals with incidentally-identified meningioma. J Neurooncol (2017) 0.75
White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiol Aging (2017) 0.75
Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain Lang (2019) 0.75
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther (2017) 0.75
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol (2017) 0.75
Pick's disease: clinicopathologic characterization of 21 cases. J Neurol (2020) 0.75
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol (2017) 0.75
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain (2019) 0.75
Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain (2019) 0.75
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y) (2017) 0.75
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst) (2019) 0.75
Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. J Alzheimers Dis (2017) 0.75
Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. J Alzheimers Dis (2015) 0.75